| Market Cap | 69.79M | P/E | - | EPS this Y | -12.30% | Ern Qtrly Grth | - |
| Income | -63.39M | Forward P/E | -1.49 | EPS next Y | 5.70% | 50D Avg Chg | -26.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -17.00% |
| Dividend | N/A | Price/Book | 0.94 | EPS next 5Y | - | 52W High Chg | -51.00% |
| Recommedations | 2.30 | Quick Ratio | 2.95 | Shares Outstanding | 25.13M | 52W Low Chg | 73.00% |
| Insider Own | 13.36% | ROA | -32.65% | Shares Float | 13.40M | Beta | -0.40 |
| Inst Own | 61.95% | ROE | -76.76% | Shares Shorted/Prior | 110.95K/218.06K | Price | 2.79 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 29,203 | Target Price | 10.00 |
| Oper. Margin | - | Earnings Date | Nov 7 | Volume | 19,066 | Change | -9.71% |
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
| Baird | Neutral | Aug 10, 23 |
| HC Wainwright & Co. | Neutral | Aug 9, 23 |
| HC Wainwright & Co. | Buy | Jun 6, 23 |
| HC Wainwright & Co. | Buy | May 12, 23 |
| SVB Leerink | Market Perform | Mar 15, 23 |
| HC Wainwright & Co. | Buy | Mar 15, 23 |
| HC Wainwright & Co. | Buy | Feb 13, 23 |
| SVB Leerink | Outperform | Jan 23, 23 |
| Citigroup | Buy | Nov 10, 22 |